Datopotamab deruxtecan  (Synonyms: DS-1062; Dato-DXd)

Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity^[1].

Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

149000 (average)

2238831-60-0

Liquid

Colorless to light yellow

[Datopotamab deruxtecan]

Shipping with dry ice.

-80°C, protect from light

• [1]. Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.  [Content Brief]